This session spotlights the latest enhancement to OmniSeq® INSIGHT—now reporting the genomic instability score (GIS) and homologous recombination deficiency (HRD) status, key biomarkers in epithelial ovarian, fallopian tube and primary peritoneal cancers. We’ll explore the therapeutic value of HRD assessment and its clinical relevance for pathologists and molecular-diagnostics laboratories. The presentation also examines the integration of germline and somatic testing to identify hereditary cancer syndromes and guide patient management. Together, these advancements deliver a more comprehensive molecular profile, enabling precision oncology approaches in gynecologic cancers.
